Full Access
Development of a Perfluorochemical Emulsion as a Blood Gas Carrier
Takao Mitsuno,
Harumasa Ohyanagi,
Kazumasa Yokoyama,
Corresponding Author
Takao Mitsuno
Kobe National Hospital, Kobe
Kobe National Hospital, Kobe, Japan.Search for more papers by this authorHarumasa Ohyanagi
Kobe National Hospital, Kobe
First Department of Surgery, School of Medicine, Kobe University, Kobe
Search for more papers by this authorKazumasa Yokoyama
Kobe National Hospital, Kobe
The Green Cross Crporation, Osaka, Japan
Search for more papers by this authorTakao Mitsuno,
Harumasa Ohyanagi,
Kazumasa Yokoyama,
Corresponding Author
Takao Mitsuno
Kobe National Hospital, Kobe
Kobe National Hospital, Kobe, Japan.Search for more papers by this authorHarumasa Ohyanagi
Kobe National Hospital, Kobe
First Department of Surgery, School of Medicine, Kobe University, Kobe
Search for more papers by this authorKazumasa Yokoyama
Kobe National Hospital, Kobe
The Green Cross Crporation, Osaka, Japan
Search for more papers by this authorAbstract
Abstract: Over 10 years of research has led to the development of a perfluorochemical (PFC) emulsion that can be utilized clinically as a blood gas carrier. The physiochemical properties of this PFC emulsion and their bio-physiological effects on animals meet the minimum requirements of an oxygen transport medium. As PFC is chemically and biochemically inert, its toxicity is extremely low. Acute toxicity was related chiefly to the particle size of the emulsion. PFC particles injected intravenously are phagocytized in the reticuloendothelial system as foreign bodies and are excreted from the lungs. The excretion rate was roughly proportional to the vapor pressure of each PFC. An emulsion consisting of 7 parts perfluorodecalin and 3 parts perfluorotripropylamine, 20% (wt/vol) PFC final, Fluosol-DA 20%, was selected as the best formulation in view of efficacy, stability, and excretion rate. No untoward reactions were observed after administration of this emulsion. More than 400 patients have received intravenous Fluosol-DA 20% in Japan.
REFERENCES
- 1 Clark LC Jr., Gollan F. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science 1966; 152: 1755–6.
- 2 Sloviter HA, Kamimoto T. Erythrocyte substitute for perfusion of brain. Nature 1969; 216: 458–60.
- 3 Geyer RP, Monroe RG, Taylor K. Survival of rats perfused with a fluorocarbon-detergent preparation. In: JC Norman, ed. Organ perfusion and preservation. New York : Appleton, Century Crofts, 1968: 85–96.
- 4 Mitsuno T., Fujita T., Sugimoto R., Matsumoto K., Matsumoto Y., Ohyanagi H., Sugihara S., Yamashita S., Sekita M., Hi-ronaka T., Ohta T. Fluorocarbon emulsion as artificial blood. [Japanese] Igaku-no Ayuini (Prog Med) 1970; 75: 637–41.
- 5 Ohyanagi H., Mitsuno T. Biophysiological effects of perfluorochemicals as artificial blood. In: R. Naito, ed. Proceedings of the Xth international congress nutrition symposium on perfluorochemical artificial blood, Kyoto. Osaka : Igaku-shobo (Medical Publisher), 1975: 21–54.
- 6 Yokoyama K., Yamanouchi K., Watanabe M., Matsumoto T., Murashima R., Daimoto T., Hamano T., Okamoto H., Suyama T., Watanabe R., Naito R. Preparation of perfluorodecalin emulsion, an approach to the red cells substitute. Fed Proc 1975; 34: 1478–83.
- 7 Ohyanagi H., Sekita M., Okamoto M., Itoh T., Mitsuno T. Exchange transfusion of blood for perfluorochemical emulsions in monkeys. Artif Organs 1978; 2 (suppl): 97–9.
- 8 Mitsuno T., Ohyanagi H. Artificial blood substitute. PFC emulsion as blood gas carrier. [Japanese]. Igaku-no Ayumi (Prog Med) 1978; 105: 553–61.
- 9 Naito R., Yokoyama K. Perfluorochemical blood substitutes, Fluosol-43, Fluosol-DA 20% and 35%. In: Technical information series, no. 5. Osaka : The Green Cross Corporation, 1978: 1–177.
- 10 Ohyanagi H., Sekita M., Yokoyama K., Itoh T., Toshima K., Okamoto M., Kawa Y., Mitsuno T. Studies on perfluorochemical emulsion (Fluosol-DA) as artificial blood in exchange transfusion and emergency use in monkeys. In: R. Naito, ed. Proceedings of the IVth international symposium on perfluorochemical blood substitutes. Amsterdam : Excerpta Medica, 1978: 373–89.
- 11 Ohyanagi H., Toshima K., Sekita M., Okamoto M., Itoh T., Mitsuno T., Naito R., Suyama T., Yokoyama K. Clinical studies of perfluorochemical whole blood substitutes:safety of Fluosol-DA (20%) in normal human volunteers. Clin Ther 1979; 2: 306–12.
- 12 Mitsuno T., Ohyanagi H., Naito R. Clinical studies of a perfluorochemical whole blood substitute (Fluosol-DA):summary of 186 cases. Ann Surg 1982; 195: 60–9.
- 13 Ohyanagi H., Itoh T., Sekita M., Okamoto M., Mitsuno T. Kinetic studies of oxygen and carbon dioxide transport into or from perfluorochemical particles. In: V. Novakova, PO Plantin, eds. Proceedings of the HS symposium. Research on perfluorochemicals in medicine and biology. Stockholm : Karolinska Institute Research Center, 1977: 114–37.
- 14 Yokoyama K., Suzuki A., Utsumi I., Naito R. Determination of particle size distribution of fluorocarbon emulsion by means of centrifugal sedimentation. A proposal for specifying the particle size distribution. Chem Pharm Bull 1974; 22: 2966–71.
- 15 Okamoto H., Yamanouchi K., Yokoyama K. Retention of perfluorochemicals in circulating blood and organs of animals after intravenous injection of their emulsions. Chem Pharm Bull 1975; 23: 1452–7.
- 16 Ohyanagi H., Sekita M., Yokoyama K., Okamoto M., Mitsuno T., Iwai M., Naito R. Experimental studies on kidney perfusion with perfluorochemical emulsion in view of graft survival. In: R. Naito, ed. Proceedings of the IVth international symposium on perfluorochemical blood substitutes. Amsterdam : Excerpta Medica, 1978: 207–24.
- 17 Yamanouchi K., Murashima R., Yokoyama K. Determination of perfluorochemicals in organs and body fluids by gas chromatography. Chem Pharm Bull 1975; 23: 1363–7.
- 18 Kamae S. Pathological studies on animals after intravenous administration of perfluorochemical (PFC) emulsion as blood gas carrier [Japanese]. Med J Kobe Univ 1979; 40: 105–21.
- 19 Mitsuno T., Tabuchi Y., Ohyanagi H., Sugiyama T. Intake and retention of perfluorochemical substance of Fluosol-DA in RES in human. In: R. Frey, B. Beisbarth, K. Stossek, eds. Proceedings of the Vth international symposium on perfluorochemical blood substitutes. Miinchen : W. Zuckschwerdt Verlag, 1981: 220–4.
- 20 Mitsuno T., Tabuchi Y., Ohyanagi H., and Sugiyama T. Further studies on intake and retention on PFC substances of Fluosol-DA by RES of humans. In: RB Bolin, RP Geyer, GJ Nemo, eds. Advances in blood substitute research. New York : Alan R. Liss, 1983: 257–63.
- 21 Ohyanagi H., Watanabe M., Okamoto H., Saito Y., Yokoyama K. RES function after administration of PFC emulsion [Japanese]. Junkan Seigyo (Circ Control) 1982; 3: 27–35.
- 22 Okamoto M., Ohyanagi H., Sekita M., Mitsuno T. Studies on the effect of administered perfluorochemical emulsion on the bone marrow function and erythrocytes metabolism. In: R. Naito, ed. Proceedings of the IVth international symposium on perfluorochemical blood substitutes. Amsterdam : Excerpta Medica, 1978: 247–56.
- 23 Naito R., Doi T., Arimura H., Suyama T. On the carcinogenicity of Fluosol-DA:studies by means of a host-mediated microbial assay for mutagenicity. In: V. Novakova, PO Plantin, eds. Proceedings of the HS symposium. Research on perfluorochemicals in medicine and biology. Stockholm : Karolinska Institute Research Center, 1977: 362–73.
- 24 Naito R., Fujita Y., Suyama T. Studies on teratogenicity of Fluosol-DA in rats. In: V. Novakova, PO Plantin, eds. Proceedings of the HS symposium. Research on perfluorochemicals in medicine and biology. Stockholm : Karolinska Institute Research Center, 1977: 332–9.
- 25 Makowski H., Tentschev P., Frey P., Necek S., Bergmann H., and Blauhut B. Tolerance of an oxygen-carrying colloidal plasma substitute in human beings. In: R. Naito, ed. Proceedings of the IVth international symposium on perfluorochemical blood substitutes. Amsterdam : Excerpta Medica, 1978: 47–54.
Citing Literature
